UNITED STATES OF
AMERICA
FOOD AND DRUG
ADMINISTRATION
CENTER FOR BIOLOGICS EVALUATION
AND RESEARCH
+ + + + +
VACCINES AND RELATED
BIOLOGICAL PRODUCTS
ADVISORY COMMITTEE
+ + + + +
MEETING ON PRESENTATION OF LABORATORY OF DNA
VIRUSES,
DIVISION OF VIRAL PRODUCTS SITE
VISIT REPORT
+ + + + +
MEETING BY
TELECONFERENCE
+ + + + +
THURSDAY, MAY 6,
2004
+ + + + +
OPEN
SESSION
This transcript has not
been edited or corrected, but appears as received from the commercial
transcribing service. Accordingly the
Food and Drug Administration makes no representation as to its accuracy.
+ + + + +
FOOD AND DRUG
ADMINISTRATION
Rockville Pike
Building 29B, Conference
Room C
Rockville,
Maryland
1:30 p.m.
+ + + + +
COMMITTEE MEMBERS PRESENT:
GARY
D. OVERTURF, M.D., Chair
MICHAEL
D DECKER, M.D., Member
MONICA
M. FARLEY, M.D., Member
RUTH
A. KARRON, M.D., Member
PHILIP
S. LARUSSA, M.D., Member
DAVID
MARKOVITZ, M.D., Member
CINDY
LYN PROVINCE, R.N., M.S.N., Member
RICHARD
WHITLEY, M.D., Member
PETER
PALESE, PH.D., Member
STEVEN
SELF, PH.D., Member
WALTER
ROYAL, III, M.D., Member
BONNIE
M. WORD, M.D., Member
CBER STAFF PRESENT
CHRISTINE
WALSH, R.N., Executive Secretary
DENISE
ROYSTER, Committee Management Specialist
KATHRYN
CARBONE, M.D., Acting Associate Director for
Research
WILLIAM
EGAN, PH.D., Acting Director, Office of
Vaccines,
Research, and Review
ANDREW
LEWIS, PH.D., Chief, Laboratory of DNA
Viruses,
Division of Viral Products
I N D E X
Announcements, Christine Walsh, FDA............. 4
Call to Order, Dr. Gary Overturf, Chair......... 8
Open Session
Laboratory
of DNA Viruses, Division of
Viral
Products
Overview
of the Laboratory, Dr. Andrew
Lewis,
FDA................................ 9
Adjourn Open Session........................... 16
P
R O C E E D I N G S
1:36
p.m.
MS.
WALSH: Good afternoon. I am Christine Walsh, the Executive
Secretary for today's meeting of the Vaccines and Related Biological Products
Advisory Committee. I would like to
welcome all of you to the 99th Meeting of the Advisory Committee.
There's
a speaker phone for public participation located here in Conference Room C of
Building 29B on the NIH Campus.
This
afternoon's session will consist of a presentation that is open to the public
and a closed session as described in the Federal Register notice of
April 19, 2004.
At
this time I would like to introduce the Committee Members and ask that they
acknowledge by saying present, if they can hear me.
The
Committee Chair, Dr. Gary D. Overturf,
Professor of Pediatrics and Pathology, University of New Mexico Medical
Center.
DR.
OVERTURF: Present.
MS.
WALSH: Our consumer representative,
Cindy Lyn Province, R.N., Associator Director of Bioethics Center of St. Louis.
MS.
PROVINCE: Present.
MS.
WALSH: Our non-voting industry
representative, Dr. Michael D. Decker, Vice President, Scientific and medical
Affairs, Aventis Pasteur.
DR.
DECKER: Present.
MS.
WALSH: Dr. Walter Royal III, Associate
Professor of Medicine, Morehouse School of Medicine.
DR.
ROYAL: Present.
MS.
WALSH: Dr. Monica M. Farley, Professor
of Medicine, Emory University School of Medicine.
DR.
FARLEY: Present.
MS.
WALSH: Dr. Ruth A. Karron, Associate
Professor, Division of International Health, Johns Hopkins School of Hygiene and
Public Health.
DR.
KARRON: Present.
MS.
WALSH: Dr. Philip S. LaRussa, Professor
of Clinical Pediatrics, Columbia University.
DR.
LaRUSSA: Present.
MS.
WALSH: Dr. Peter Palese, Chairman and
Professor of Department of Microbiology, Mt. Sinai School of Medicine?
DR.
PALESE: Present.
MS.
WALSH: Dr. Bonnie M. Word, Assistant
Professor of Pediatrics, Baylor College of Medicine, Texas Children's Hospital.
DR.
WORD: Present.
MS.
WALSH: Dr. Steven Self, Professor,
Department of Biostatistics, University of Washington.
DR.
SELF: Present.
MS.
WALSH: Dr. David Markovitz, Professor,
Division of Infectious Diseases, University of Michigan Medical Center.
DR.
MARKOVITZ: Present.
MS.
WALSH: Dr. Richard Whitley, Professor,
Pediatrics, Microbiology and Medicine, University of Alabama at
Birmingham.
Dr.
Whitley did tell me he may be joining us a little bit late today.
I
would like to thank all Committee Members for taking time to join us today.
I
would also like to make one announcement regarding a future VRBPAC
meeting. There will be no meeting held
on the reserved alternate dates of July 29th and 30th. After today's meeting, the next VRBPAC
meeting is scheduled for September 22nd and 23rd, 2004.
Now
I would like to introduce some FDA CBER Staff Members present at today's
meeting and are currently seated in the room.
Dr.
Kathryn Carbone, Acting Associate Director for Research; Dr. William Egan,
Acting Director, Office of Vaccines, Research and Review; Dr. Andrew Lewis,
Chief, Laboratory of DNA Viruses, Division of Viral Products, OVRR; and Denise
Royster, Committee Management Specialist, VRBPAC Advisory Committee who worked
very hard in making today's meeting a success.
Thank you, Denise.
I
ask that all our Committee Members identify themselves each time they
speak. We have a transcriber present
who will need your assistance in order to accurately transcribe all comments to
the appropriate Committee Member.
I
also ask our Committee Members do not use cellular phones since that can add
extra unnecessary background to the line, noise to the line. Should
during the teleconference a source of noise occur in your office, we would
appreciate it if you would use the mute button on your phone if you have that
option. We ask that you do not place us
on hold because many clinical centers have background music that can be very
distracting to those remaining on the teleconference line.
I
would now like to read into public record the conflict of interest statement
for this meeting.
The
following announcement addresses conflict of interest issues associated with
today's meeting of the Vaccines and Related Biological Products Advisory
Committee on May 6th related to the review and discussion of the intramural
research programs of the Laboratory of DNA viruses, Division of Viral
Products. Based on the agenda made
available, it has been determined that the Committee discussions present no
potential for a conflict of interest.
That
ends the reading of the conflict of interest statement.
Dr.
Overturf, I turn the meeting over to you.
DR.
OVERTURF: Thank you. This is Dr. Overturf and I'd like to welcome
the Members of the Committee to this meeting.
The purpose of this meeting is to review the site visit report of the
Laboratory of DNA Viruses which is in the Division of Viral Products in the
Office of Vaccines, Research and Review.
You
should have all received prior to this time either by e-mail or by direct mail
the prior documents which include, among other things, the site report visit
itself which is a document in which the chair of the Committee, Dr. Walter
Royal is listed at the top of the page.
The
first speaker today will be Dr. Andrew Lewis from the FDA and I will turn the
meeting at this time over to Dr. Lewis.
DR.
LEWIS: Thank you, Dr. Overturf. I'm Andrew Lewis, Chief of the Laboratory in
DNA Viruses, Division of Viral Products.
It's
my job today to present the Committee with a brief summary of the Laboratory of
DNA Viruses in preparation for your discussion of our site visit. The
Laboratory of DNA Viruses is an organizational unit within the Division of
Viral Products. The mission of our
laboratory is basically fourfold.
First, we evaluate and regulate vaccines and other products involving
DNA viruses, including pox viruses, herpes viruses, adenoviruses, and
paplomaviruses.
Second,
we review and provide consultations to other CBER offices on submissions using
DNA viruses as recombinant gene delivery systems.
Third,
we evaluate and provide consultations on issues related to cell substrates and
adventitious agents.
And
last, but not least, we strive to maintain DDP in CBER's intellectual base by
doing research on DNA viruses and cell substrates.
I
would like to point out to the Committee that managing these responsibilities
requires constant attention of a laboratory staff with regard to the use of the
limited time and resources that are available.
In looking back over the past several years, I feel quite good about the
way our staff has performed in managing its resources.
The
Laboratory of DNA Viruses was established in 1988 and it is composed of four
research teams. These teams include the
Unit on Cell Substrates headed by myself with a staff of four; the Unit on DNA
Virusing Expressing headed by Jerry Weir with a staff of three; the Unit on Pox
Virus Biology headed by Mike Merchlinsky with a staff of six; the Unit of Viral
Latency headed by Phil Krause, also with a staff of six.
More
details about each of these units are provided in their site visit book which I
believe each of you has a copy of.
Concerning
the staff of the Laboratory, I should also point out that in 2000, Jerry Weir
was appointed Director of the Division of Viral Products and later that same
year, Phil Krause, from the Latency Unit, was appointed the Deputy Director of
the Division of Viral Products.
The
principal regulatory responsibilities of our laboratory include the review of
investigational new drug applications and biologics license applications for
DNA virus products. The laboratory is a
unit within the Division of Viral Products in the Office of Vaccines with the
prime responsibility for reviewing, licensing and managing post-licensure
issues associated with chicken pox and smallpox vaccines.
The
laboratory is also responsible for the evaluation of plasma infectors, uses
vaccines for DNA virus in new diseases and we share the responsibility for
evaluation of DNA viruses used for gene therapy.
In
addition, the laboratory evaluates and advises on cell substrate and
adventitious agent issues within the Office.
The
laboratory is involved with all aspects or the regulation of products involving
DNA viruses as well as cell substrates used for the manufacture of viral
vaccines. Our regulatory
responsibilities encompass all phases of product development from pre-IND
guidance, IND submissions, product license application and supplements,
post-marketing commitments and vaccine lot release.
The
review workload handled by the laboratory over the period covered by the
present site visit has increased significantly. In 1997, the laboratory was responsible for the review of 178
INDs. These included original
submissions as well as amendments and in 2003, the laboratory reviewed 246
INDs, 12 biologic license application supplements and released 342 lots of
combined chicken pox and smallpox vaccines.
The
laboratory typically receives and reviews approximately 10 original submissions
each year and 250 to 300 supplements.
In
addition to the user regulatory work, our laboratory is also involved in
numerous other activities that are an integral part of our regulatory
mission. These activities include
organizing and participating in discussions with you as our Advisory Committee;
inspecting vaccine manufacturing facilities; developing regulatory guidance
documents; serving as FDA experts to international bodies such as the World
Health Organization; and organizing international workshops.
The
program report provided by each laboratory unit in the site visit book contains
much more information about these activities.
The
research programs in the laboratory are designed to complement and support our
regulatory mission by focusing on issues that we believe to be critical to the
evaluation, development and safety of the products related to DNA viruses and
by investigating the basic mechanisms of biology and pathogenesis of the
viruses and products we regulate. To
give you a very brief look at some of our research projects, the Unit on Cell
Substrates is developing an assay or attempting to develop an assay to assess
the potential risk of the oncogenic activity of DNA from continuous cell lines
and has evaluated concerns about the ability of VERO cells to evolve from
non-tumorgenic to tumorgenic phenotypes by tissue culture passage. The Unit of Viral Gene Expression and the
Unit on Pox Virus Biologies are collaborating to develop data regarding
protected immunity, new generation of smallpox vaccines and to determine the
relative importance of different aspects of the immune response to smallpox
vaccines. One or more of these
responses might be possible surrogates that can be used to evaluate the
efficacy of new smallpox vaccines.
In
addition to its on-going work, the mechanisms of viral latency, the Unit on
Latency is developing nonspecific methods to detect adventitious agents which
include the use of nanovirus sensors for virus detection as well as degenerate PCR mechanisms.
To
support these research activities, the four units of the laboratory brought in
over $700,000 to CBER in 2003 and I think I can be frank by saying that without
these funds, it would not have been possible for us to maintain our research
programs at their current levels.
Some
of the major things that we've accomplished over the past five years include
the re-licensure of the Smallpox Vaccine Drive Acts, receiving a patent for the
in vitro ligation of foreign DNA in large eucaryotic vectors, identifying
sequence differences between vaccine strain and wild type chicken pox viruses,
identifying virus reactivation as a potential for persistent immunity in
chicken pox vaccinees, organizing and publishing the proceedings of an
international workshop on cell substrates in 1999, stimulating work on SV-40 as
a potential human polymer virus by developing small working groups and funding
small projects at other institutions.
I
think this sort of concludes my summary of the laboratory's activities. I would like at this time to express our
appreciation to those Members of the Committee and to the Committee itself for
participating in this review and commenting on our progress.
Thank
you very much.
DR.
OVERTURF: Thank you very much, Dr.
Lewis. Before we proceed, we need to
request from the FDA whether there have been members of the public or others
who wish to speak in the Open Public Hearing.
MS.
WALSH: I see no one in the room right
now, Dr. Overturf.
DR.
OVERTURF: Okay, with that, we can
dispense with the statement on the Open Public Hearing. And we can proceed with the rest of the
session and the next speaker is Dr. Walter Royal, who will present the results
of the site visit report.
DR.
ROYAL: Thank you, Dr. Overturf --
MS.
WALSH: Excuse me, excuse, this is
Christine for one second. Can we just
hold up for one second?
DR.
OVERTURF: Before we go to closed
session?
MS.
WALSH: Yes, before we go into closed
session.
DR.
OVERTURF: that would be fine.
MS.
WALSH: With the report from Dr. Royal,
we'll be moving into a closed session.
So anyone that would need to leave right now -- and before we do that,
any questions for Dr. Lewis before he leaves, from the Committee?
DR.
OVERTURF: Are there any questions for
Dr. Lewis?
DR.
LEWIS: Thank you.
MS.
WALSH: Thank you, Dr. Lewis. And prior to that, we'll just go into closed
session now.
(Whereupon
at 1:52 p.m., the open session was concluded.)